By Vicente LLP, Psychedelic Alpha
Apr 6, 2024
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #10 focuses on updates from the recent meeting of the Natural Medicine Advisory Board, where draft rules for Facilitator licensing and training were discussed.
By Meg Nash, Bridgette Nikisher
Apr 4, 2024
The Maryland Cannabis Administration published proposed Emergency Regulations with significant changes, including requirements for proof of capitalization and new limitations on Management Agreements concerning branding and capping annual fees. Read this Insights article for the top things to know about the new regulations.
By Andrea Golan, Genevieve Meehan
Apr 1, 2024
For years, the efficacy of cannabis lab test results has been widely discussed across the California cannabis industry due to inflated potency test results and inconsistencies in results due to labs using different methodologies for testing cannabis. This has changed with the implementation of lab testing standardization.
By Jason Adelstone
Mar 21, 2024
The International Narcotics Control Board (INCB) may be taking a more measured approach to cannabis. In their 2023 report, INCB used the word "may" when discussing potential inconsistencies between US state legalization and international treaties. This subtle shift in language suggests a more open-minded approach. This blog post explores the significance of this change in the report’s language and what it might mean for the future of global cannabis legalization.
By Vicente LLP, Psychedelic Alpha
Mar 20, 2024
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #9 focuses on updates from the recent meeting of the Natural Medicine Advisory Board and listening sessions held by the Department of Revenue and the Department of Regulatory Agencies Stakeholder Engagement Meeting.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.